IMR Press / FBL / Volume 30 / Issue 6 / DOI: 10.31083/FBL31309
Open Access Original Research
Sodium-Dependent Glucose Transporter-2 Inhibitor Enhances the Hypotensive Effect of Renal Denervation by Inhibiting Sympathetic Activity and Inflammatory Reaction
Show Less
Affiliation
1 Department of Cardiovascular, Clinical School of Cardiovascular Disease, Tianjin Medical University, 300450 Tianjin, China
2 Department of Cardiovascular, Tianjin First Center Hospital, 300110 Tianjin, China
3 Department of Chronic Disease, Center for Disease Control and Prevention in Hanzhong, 723000 Hanzhong, Shaanxi, China
4 Department of Cardiovascular, Hanzhong Nanzheng People’s Hospital, 723102 Hanzhong, Shaanxi, China
5 Institute of Cardiovascular Disease, Characteristic Medical Center of People’s Armed Police Force, 300000 Tianjin, China
6 Department of Cardiovascular, The First Central Clinical School, Tianjin Medical University, 300110 Tianjin, China
7 School of Medicine, Nankai University, 300191 Tianjin, China
*Correspondence: lucz@126.com (Chengzhi Lu); cardiolab@live.com (Yuming Li)
These authors contributed equally.
Front. Biosci. (Landmark Ed) 2025, 30(6), 31309; https://doi.org/10.31083/FBL31309
Submitted: 21 November 2024 | Revised: 22 December 2024 | Accepted: 31 December 2024 | Published: 30 June 2025
Copyright: © 2025 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract
Background:

Sodium-dependent glucose transporter-2 inhibitors (SGLT-2i) have potential hypotensive effects, enhancing the hypotensive effect of renal denervation (RDN). Spontaneously hypertensive rats (SHRs) were used to verify this hypothesis and explore the associated underlying pathways.

Methods:

Seven Wistar-Kyoto (WKY) rats and 35 SHRs were divided into 6 groups. The blank WKY control (W) group consisted of all 7 WKY rats, whereas the SHRs were divided into the following groups, each containing 7 rats: sham operation (Sham), renal denervation (RDN), SGLT-2 inhibitor treatment (SGLT-2i), and the combination of renal denervation with SGLT-2 inhibitor treatment (RDN+SGLT-2i). The rats in the RDN+SGLT-2i and SGLT-2i groups were gavaged with dapagliflozin (DAPA) before RDN. The sham group was subjected to a sham operation. One-week post-operation, rat tail manometry, and echocardiography were subsequently performed, and peripheral blood inflammatory cells were detected via flow cytometry before sample collection. Following sample collection, the serum, including interleukin-6, angiotensin-II, renin, and norepinephrine, was tested via enzyme-linked immunosorbent assay. Pathological testing included Masson staining of the myocardial tissue, tyrosine hydroxylase (TH) immunohistochemistry, and Fos protooncogene (C-Fos) immunofluorescence staining of the hypothalamus tissue.

Results:

Compared with RDN alone, RDN following intragastric DAPA administration reduced systolic blood pressure (SBP) in SHRs, independent of its hypoglycemic effect. Compared with the RDN group, the pathological results of the RDN+SGLT-2i group revealed a greater improvement in the intensity of TH staining in the hypothalamus tissue, closer to the normal level of the cross-sectional area in myocardial cells. Furthermore, we observed enhanced sympathetic inhibition in the brain and a reduction in the fibrotic area within myocardial cells. Additionally, the proportions of inflammatory mononuclear cell subsets and the levels of inflammatory factors improved. Although DAPA reduced inflammation and sympathetic nerve overexcitation alone, it could not completely reverse blood pressure (BP) or cardiac function. Similarly, the alleviation of inflammation and BP reduction in RDN-treated rats were inferior to those in rats treated with RDN combined with DAPA.

Conclusions:

Compared with RDN alone, DAPA addition before RDN can considerably reduce the BP of SHRs. The enhancement of the hypotensive effect may be attributed to the inhibition of sympathetic activity and the reduction in inflammatory reactions.

Keywords
sodium-dependent glucose transporter-2 inhibitor
blood pressure
renal denervation
inflammation
hypertension
Funding
82300445/ National Natural Science Foundation of China
82470294/ National Natural Science Foundation of China
TJYXZDXK-054B/ Tianjin Key Medical Discipline (Specialty) Construction Project
22JCQNJC01130/ Natural Science Foundation of Tianjin
Figures
Fig. 1.
Share
Back to top